全球腹水市场 – 行业趋势和 2029 年预测

腹水市场??????分析和规模

腹水可能是由甲状腺功能减退、肾病综合征和女性卵巢疾病引起的。这种疾病通常表现为恶心、胃灼热、胃部不适、呕吐、呼吸短促和腹部肿胀。主要市场参与者一直专注于研发活动，这些活动带来了创新和新产品的推出，促进了腹水市场的增长。

Data Bridge Market Research 分析了 2022-2029 年预测期内全球腹水市场的增长率。在上述预测期内，全球腹水市场的预期复合年增长率趋于 4.50% 左右。2021 年市场价值为 23.9 亿美元，到 2029 年将增长至 34 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

腹水市场范围和细分

Market Definition

Ascites is the condition wherein an abnormal accumulation of fluid occurs within the peritoneal cavity. It usually occurs because of liver malfunctions; when the liver stops working properly or fluid fills the space between the abdominal lining and other organs. Several patients suffering from liver cirrhosis, stomach cancer, congestive heart failure or tuberculosis are at major risk of getting ascites. This disease prevalence is rising and important diagnostic procedures and treatments will boost the growth of the market.

Global Ascites Market Dynamics

Drivers

• Increased Rate of Ovarian Cancer

Ovarian cancer ranks fifth in women's cancer deaths, resulting in more deaths than any other cancer. Any female having the risk of getting ovarian cancer during her lifetime is around 1 in 78. According to the data published by National Cancer Institute, around 1.3% of women will be diagnosed with ovarian cancer at some point in their lifetime. Thus boosting the market growth.

• Higher Rate of Drug Approvals and Launches       

An extensive range of new generation therapeutics targets, including novel small molecules and cellular therapy, are currently under process. These include mongersen, tofacitinib, ustekinumab, and vedolizumab. This influx is expected to be a consequence of rising prevalence of gastrointestinal diseases worldwide. In addition to this, drugs also form the first line of treatment in ascites management and in the coming future, strong drug pipeline is expected to provide highly effective drug molecule. Thus, all these developments are boosting the growth of the market.

Opportunities

• High-end Efficiency of Biologics

Some studies have stated that biologics show greater long-term efficiency. According to a study which University of Chicago conducted, it was witnessed that the usage of biologics has resulted in a complete decrease in the number of surgeries by about 40.0%, emergency room visits by 60.0%, and hospitalizations by 50.0%. All these factors are also contributing in the growth of the market.  

• The Wide Application of Generic Drugs

Branded drug manufacturers and generic producing firms are joining up together for the production of generic drugs after patent expiry, which is projected to lift the growth of generics. In addition, major firms are gradually focusing on developing generics due to the increase in off-patented drugs in the market. Although, marketing exclusivity given by the FDA to patent holders for several indications is predicted to hamper market growth to a slight extent.

Restraints/Challenges

• Higher Expenditure Associated With Ascites Treatment

High-end expenditure regarding the drug manufacturing and development process are hampering the market's growth. High initial investment required in the R&D activities for developing vaccines, drugs, and kits used in the treatment are restraining growth of the global ascites market.

• Unavailability of Appropriate Treatments

To treat conditions which are rare, many a times all treatments are not available, especially in under-developed countries. The severe patients needs to be treated with the advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.

This global ascites market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ascites market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Ascites Market Scope

The global ascites market is segmented on the basis of types, diagnosis, treatment, route of administration,end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Transudative
• Exudative
• Others

Diagnosis

• Ultrasound
• CT Scan
• MRI
• Blood Test
• Laparoscopy
• Angiography
• Others

Treatment

• Medication
• Paracentesis
• Surgery
• Others 

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Ascites Market Regional Analysis/Insights

The global ascites market is analyzed and market size insights and trends are provided by types, diagnosis, treatment, route of administration,end-user, distribution channel as referenced above.

The major countries covered in the global ascites market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

由于存在产品的关键制造、高水平的研发、医疗保健支出和技术熟练的专业人员，北美被认为在预测期内具有最高的利润增长。

由于政府宣传活动的加强、肾衰竭和肺结核患病率的上升以及仿制药制造商的存在，亚太地区占据了市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球腹水市场份额分析

全球腹水市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球腹水市场的关注有关。

全球腹水市场的主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• 太阳制药工业有限公司 (印度)
• 默克公司（美国）
• 礼来（美国）
• WOCKHARDT（印度）

SKU-55200